Research
UBS Upgrades Illumina to Buy From Neutral, Adjusts Price Target to $260 From $135
Illumina (ILMN) has an average rating of overweight and mean price target of $193.61, according to analysts polled by FactSet.
$ILMN
$ILMN
16 stories mentioning ILMNUpdated 4d ago
Every FINWIRES story that references ILMN, newest first.
What are analysts saying about ILMN?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on ILMN?
Insider Trading
Illumina Insider Sold Shares Worth $57,199,201, According to a Recent SEC Filing
Keith A. Meister, Director, on September 02, 2026, sold 263,560 shares in Illumina (ILMN) for $57,199,201. Following the Form 4 filing with the SEC, Meister has control over a total of 777,130 common shares of the company, with 6,780 shares held directly and 770,350 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1110803/000119312526383924/xslF345X05/ownership.xml
$ILMN
Insider Trading
Illumina Insider Sold Shares Worth $85,241,664, According to a Recent SEC Filing
Keith A. Meister, Director, on August 25, 2026, sold 375,941 shares in Illumina (ILMN) for $85,241,664. Following the Form 4 filing with the SEC, Meister has control over a total of 1,040,690 common shares of the company, with 6,780 shares held directly and 1,033,910 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1110803/000119312526371756/xslF345X05/ownership.xml
$ILMN
Insider Trading
Illumina Insider Sold Shares Worth $145,556,398, According to a Recent SEC Filing
Keith A. Meister, Director, on August 19, 2026, sold 679,574 shares in Illumina (ILMN) for $145,556,398. Following the Form 4 filing with the SEC, Meister has control over a total of 1,416,631 common shares of the company, with 6,780 shares held directly and 1,409,851 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1110803/000119312526361476/xslF345X05/ownership.xml
$ILMN
Wire
Illumina Building Clinical Momentum Amid Fading Competition, RBC Capital Markets Says
Illumina (ILMN) is building clinical momentum as competitive concerns surrounding the company are fading, RBC Capital Markets said in a note Monday.The company's clinical sequencing revenue could grow at a durable mid-teens rate, driven by volume growth in oncology and easing pricing headwinds, according to the note.RBC said that while customers are expected to evaluate competitive sequencing instruments, Illumina will likely retain its clinical market share.Sequencing instrument sales could decline double digits in 2027 as they face more headwinds than previously expected, but clinical sequencing and sequencing services could offset this decline, the firm added.RBC Capital Markets has an outperform rating and a $230 price target on the stock.Price: $191.86, Change: $+0.07, Percent Change: +0.04%
$ILMN
Wire
Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences
Standard BioTools (LAB) said Tuesday that it has agreed to sell its Mass Cytometry business to Multiplex Bio as part of efforts to advance its previously announced merger with Treeline Biosciences.The Mass Cytometry deal is valued at up to $10 million, consisting of a seller's note issued by Multiplex Bio and a potential milestone payment, Standard BioTools said, adding it has also agreed to provide Multiplex Bio with a working capital loan of up to $10 million at closing of the transaction.Additionally, Standard BioTools said it received $30 million as a buyout of the 2026 earnout and all accrued and unpaid royalty payments related to Illumina's (ILMN) previously completed acquisition of Standard BioTools' SomaLogic business. The payment will be included in Standard BioTools' pro forma net cash position at closing of the Treeline transaction, the company said.Standard BioTools also said it expects the Treeline transaction to close by the end of 2026 and that the US Federal Trade Commission has provided early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
$ILMN$LAB
Research
JPMorgan Upgrades Illumina to Overweight From Neutral, Price Target is $185
Illumina (ILMN) has an average rating of overweight and mean price target of $147.88, according to analysts polled by FactSet.
$ILMN
Insider Trading
Illumina Insider Sold Shares Worth $107,042,631, According to a Recent SEC Filing
Keith A. Meister, Director, on May 28, 2026, sold 669,596 shares in Illumina (ILMN) for $107,042,631. Following the Form 4 filing with the SEC, Meister has control over a total of 2,837,090 common shares of the company, with 6,638 shares held directly and 2,830,452 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1110803/000101143826000371/xslF345X05/form4.xml
$ILMN
Sectors
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) climbed 1.5%.In corporate news, Eli Lilly's (LLY) weight-loss drugs secured coverage from the three largest US pharmacy benefit managers, the drugmaker said Thursday. Lilly shares gained 4.3%.Agilent Technologies (A) stock jumped 18% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Illumina (ILMN) shares climbed 5% after it said it launched a whole-genome sequencing research workflow for molecular residual disease detection.AstraZeneca's (AZN) durvalumab, plus Bacillus Calmette-Guerin, received approval by the Food and Drug Administration to treat adults with BCG-naive, high-risk non-muscle invasive bladder cancer, the FDA said Thursday. AstraZeneca shares rose 0.2%.
$A$AZN$ILMN$LLY
Sectors
Sector Update: Healthcare Stocks Gain Thursday Afternoon
Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.2%.The iShares Biotechnology ETF (IBB) increased 1.1%.In corporate news, Eli Lilly's (LLY) weight-loss drugs secured coverage from the three largest US pharmacy benefit managers, the drugmaker said Thursday. Lilly shares gained 3.6%.Agilent Technologies (A) stock jumped 19% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Illumina (ILMN) shares climbed 4.9% after it said it launched a whole-genome sequencing research workflow for molecular residual disease detection.Cogent Biosciences (COGT) shares added 2.4% after it said the US Food and Drug Administration has accepted its new drug application for bezuclastinib plus sunitinib to treat patients with gastrointestinal stromal tumors who have been treated with imatinib previously.
$A$COGT$ILMN$LLY
Wire
Illumina Launches Whole Genome Cancer Research Workflow
Illumina (ILMN) said Thursday it launched a whole-genome sequencing research workflow for molecular residual disease detection and opened early access to select clinical research partners.The company said the workflow is expected to support residual disease detection and cancer genomic profiling using solid tumor and blood samples.Illumina said the workflow can complete processing in about five days and targets analytical sensitivity down to 10 parts per million for certain tumors.The company said its Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise.Illumina said it plans a broader commercial launch next year and is developing an additional workflow designed to support lower detection thresholds using NovaSeq X systems.Price: $153.98, Change: $+3.81, Percent Change: +2.54%
$ILMN
Wire
Illumina's Mid-Teens Clinical Growth Appears Sustainable Over Next 1 to 2 Years, RBC Says
Illumina's (ILMN) mid-teens clinical growth appears sustainable over the next one to two years, driven largely by oncology testing and screening applications, as the company sees building clinical momentum and fading competitive concerns, RBC said in a Thursday note.With clinical markets now comprising over 50% of the company's sales, growth has accelerated to 20% in each of the past two quarters, supported by robust growth forecasts for Illumina's oncology customers, according to the note.Illumina sees fading competitive concerns with Roche's Axelios 1 sequencing update seeing mixed response, RBC said, adding that it did not see any updates at Roche's investor event earlier this week to change the narrative.Additionally, RBC said that the weakness Illumina is seeing in academic demand is an industry-wide problem and that several new product launches should enable demand to at least flatten by next year, which will be enough to meet or exceed Wall Street forecasts.RBC has an outperform rating on the company, with a $170 price target.Price: $139.93, Change: $-3.31, Percent Change: -2.31%
$ILMN
Research
Daiwa Securities Upgrades Illumina to Outperform From Neutral, Adjusts Price Target to $155 From $128
Illumina (ILMN) has an average rating of overweight and mean price target of $140.71, according to analysts polled by FactSet.
$ILMN
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Illumina
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $161 from $140, 31x our 2026 EPS estimate (up to $5.18 from $5.13; 2027 estimate up to $5.89 from $5.81), a premium to ILMN's one-year historical forward average of 24x. We were encouraged by ex-China organic sales rising ~3.5% Y/Y in Q1, while adjusted operating margin rose 150 bps Y/Y to 21.9%. We look positively on recent Congressional action to modestly increase the National Institutes of Health (NIH) budget (~1%) rather than the dramatic cuts initially feared by investors, though ILMN's guidance implies continued pressure in academic end markets in 2026. Excluding China, sequencing consumables within research and applied was down 12% Y/Y in Q1, though clinical consumables sales rose 20% Y/Y. Positively, ILMN placed over 80 NovaSeq X instruments (up 20 Y/Y) during the quarter, indicating strong momentum.
$ILMN
Research
Research Alert: Illumina: Sequencing Sales Growth Supports Q1 Eps Beat, Guidance Increased
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Illumina reported Q1 2026 adjusted EPS of $1.15, up 18.6% Y/Y and beating the $1.05 consensus estimate, while revenue grew 4.8% to $1.091B. Operating leverage was evident, with adjusted operating margin expanding 150 bps Y/Y to 21.9% due to consumables growth of 4.3% to $726M and instruments up 8.3% to $118M. The instrument growth suggests continued NovaSeq X adoption momentum, while rest-of-world organic revenue growth of 3.5% indicates healthy demand outside of China (declined 29% organically). ILMN raised full-year guidance, increasing revenue expectations by $20M at the midpoint to $4.52B-4.62B and adjusted EPS to $5.15-5.30 from $5.05-5.20. We view the recently-completed SomaLogic acquisition positively, as it expands ILMN's addressable market into proteomics and strengthens its multiomics portfolio. Strong cash generation was also present, with operating cash flow up 20.4% to $289M, supporting the newly-authorized $1.5B share repurchase program.
$ILMN
Wire
Illumina, Data-Driven Discovery in Biomedicine Collaborate to Advance Pediatric Cancer, Rare Disease Research
Illumina (ILMN) and the Center for Data-Driven Discovery in Biomedicine said Tuesday they have launched a data partnership to advance research in pediatric cancer and rare diseases.Under the initiative, D3b will analyze 100,000 whole genomes from pediatric patients using Illumina software to build a unified genomic dataset.The data will be made available through the Gabriella Miller Kids First Data Resource Center to support research and clinical insights, the companies said.The dataset will include genomes from patients with rare congenital conditions and cancers collected through federally funded programs, including the Children's Brain Tumor Network.Illumina is also joining the Pediatric Care eXpansion program of the Advanced Research Projects Agency for Health, aimed at accelerating diagnosis and treatment by expanding data-sharing across more than 200 pediatric institutions in the US, according to a joint statement.Price: $129.43, Change: $+2.47, Percent Change: +1.95%
$ILMN
